The recent development and now widespread use of CFTR modulator therapies for various class mutations have single-handedly revolutionized current CF care treatment strategies for 90–95% of the Australian CF population of over 3600 patients eligible for these agents (notwithstanding current accessibility barriers in many parts of the world) [12]. This evidence concerns the gene CFTR and cystic fibrosis.